213 related articles for article (PubMed ID: 8911750)
1. Irinotecan (CPT-11): a brief overview.
Rivory LP
Clin Exp Pharmacol Physiol; 1996; 23(10-11):1000-4. PubMed ID: 8911750
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of CPT-11. Impact on activity.
Rivory LP
Ann N Y Acad Sci; 2000; 922():205-15. PubMed ID: 11193896
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of irinotecan.
Chabot GG
Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
[TBL] [Abstract][Full Text] [Related]
4. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.
Ikegami T; Ha L; Arimori K; Latham P; Kobayashi K; Ceryak S; Matsuzaki Y; Bouscarel B
Cancer Res; 2002 Jan; 62(1):179-87. PubMed ID: 11782376
[TBL] [Abstract][Full Text] [Related]
5. Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
van Ark-Otte J; Kedde MA; van der Vijgh WJ; Dingemans AM; Jansen WJ; Pinedo HM; Boven E; Giaccone G
Br J Cancer; 1998 Jun; 77(12):2171-6. PubMed ID: 9649129
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacology of camptothecin and its derivatives].
Rivory LP; Robert J
Bull Cancer; 1995 Apr; 82(4):265-85. PubMed ID: 10846537
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of CPT-11 and its active metabolite SN-38.
Lavelle F; Bissery MC; André S; Roquet F; Riou JF
Semin Oncol; 1996 Feb; 23(1 Suppl 3):11-20. PubMed ID: 8633248
[TBL] [Abstract][Full Text] [Related]
8. Camptothecin analogues with enhanced antitumor activity at acidic pH.
Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Mathijssen RH; Loos WJ; Verweij J; Sparreboom A
Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913
[TBL] [Abstract][Full Text] [Related]
10. Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats.
Kaneda N; Hosokawa Y; Yokokura T; Awazu S
Biol Pharm Bull; 1997 Sep; 20(9):992-6. PubMed ID: 9331983
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of irinotecan disposition and toxicity: a review.
Fujita K; Sparreboom A
Curr Clin Pharmacol; 2010 Aug; 5(3):209-17. PubMed ID: 20406168
[TBL] [Abstract][Full Text] [Related]
12. Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38.
Sadzuka Y; Hirotsu S; Hirota S
Jpn J Cancer Res; 1999 Feb; 90(2):226-32. PubMed ID: 10189894
[TBL] [Abstract][Full Text] [Related]
13. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms.
Haaz MC; Rivory LP; Riché C; Robert J
Naunyn Schmiedebergs Arch Pharmacol; 1997 Aug; 356(2):257-62. PubMed ID: 9272733
[TBL] [Abstract][Full Text] [Related]
14. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
[TBL] [Abstract][Full Text] [Related]
15. Human multidrug resistance associated protein 4 confers resistance to camptothecins.
Tian Q; Zhang J; Tan TM; Chan E; Duan W; Chan SY; Boelsterli UA; Ho PC; Yang H; Bian JS; Huang M; Zhu YZ; Xiong W; Li X; Zhou S
Pharm Res; 2005 Nov; 22(11):1837-53. PubMed ID: 16132345
[TBL] [Abstract][Full Text] [Related]
16. The current status of camptothecin analogues as antitumor agents.
Slichenmyer WJ; Rowinsky EK; Donehower RC; Kaufmann SH
J Natl Cancer Inst; 1993 Feb; 85(4):271-91. PubMed ID: 8381186
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of irinotecan.
Robert J; Rivory L
Drugs Today (Barc); 1998 Sep; 34(9):777-803. PubMed ID: 14988754
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
Cancer Chemother Pharmacol; 1998; 42(4):280-6. PubMed ID: 9744772
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients.
Rivory LP; Chatelut E; Canal P; Mathieu-Boué A; Robert J
Cancer Res; 1994 Dec; 54(24):6330-3. PubMed ID: 7987823
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats.
Machida Y; Onishi H; Kurita A; Hata H; Morikawa A; Machida Y
J Control Release; 2000 May; 66(2-3):159-75. PubMed ID: 10742577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
